WC
STLN

Wexford Capital’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Wexford Capital’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.25M Buy
1,711,323
+177,867
+12% +$545K 0.76% 19
2025
Q4 		$5.46M Sell
1,533,456
-37,613
-2% -$139K 1.05% 16
2025
Q3 		$5.48M Buy
1,571,069
+452,390
+40% +$1.55M 0.79% 16
2025
Q2 		$2.29M Buy
+1,118,679
New +$2.8M 0.64% 30

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wexford Capital's STLN Position: Q1 2026 in Review

Wexford Capital increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 12% in Q1 2026, buying an estimated $545K and bringing the position to 1,711,323 shares worth $5.25M. The position accounts for 0.76% of the portfolio, ranked #19.

Wexford Capital first reported a position in STLN in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.48M in Q3 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Wexford Capital held 1,711,323 shares of Starling Oncology Institute, Inc. Common Stock worth $5.25M as of Q1 2026.
  • Wexford Capital bought 177,867 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $545K.
  • Starling Oncology Institute, Inc. Common Stock made up 0.76% of Wexford Capital's portfolio in Q1 2026, its #19 holding.
  • Wexford Capital first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2025 and has held it in 4 quarters since.
  • Wexford Capital's Starling Oncology Institute, Inc. Common Stock position peaked at $5.48M in Q3 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Wexford Capital's 13F filing for Q1 2026, filed 15 May 2026.